Systemic therapy for advanced endometrial cancer;Traitement systémique du cancer de l'endomètre avancé

Bulletin du Cancer

Volumn 99, Issue 1, 2012, Pages 93-97

  Tazi, Youssef ^a   Pautier, Patricia ^a   Lhommé, Catherine ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Endometrial cancer; Hormonal therapy; Targeted therapy

Indexed keywords

ANTHRACYCLINE; HORMONE RECEPTOR; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; ENDOMETRIUM CANCER; HUMAN; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SYSTEMIC THERAPY; TREATMENT RESPONSE;

EID: 84856587868     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1523     Document Type: Article

References (29)

1. Projections de l'incidence et de la mortalité par cancer en France en 2010. http://www.invs.sante.fr/applications/cancers/projections2010/default. htm.
2. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17 : 1736-44. (Pubitemid 29269242)
3. Thigpen T, Blessing J, Disaia P, Ehrlich C. Oral medroxyprogesterone acetate in advanced or recurrent endometrial carcinoma: results of therapy and correlation with estrogen and progesterone receptor levels. The Gynecologic Oncology Group experience. In : Baulier E, Iacobelli S, McGuire WW, editors. Endocrinology and malignancy. Pearl River, NY: Parthenon Publishers, 1986, p. 446-54.
4. Whitney CW, Brunetto VL, Zaino RJ, et al, Gynecologic Oncology Group study. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92 : 4-9. (Pubitemid 38147364)
5. Fiorica JV, Brunetto VL, Hanjani P, et al, Gynecologic Oncology Group study. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92 : 10-4. (Pubitemid 38147365)
6. Thigpen JT, Brady MF, Homesley HD. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2001; 19 : 364-7. (Pubitemid 32112847)
7. Burke TW, Walker CL. Arzoxifene as therapy for endometrial cancer. Gynecol Oncol 2003; 90 : S40-6.
8. Covens AL, Filiaci V, Gersell D, et al. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2011; 120 : 185-8.
9. Ma BB, Oza A, Eisenhauer E, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 2004; 14 : 650-68.
10. Rose PG, Brunetto V, Vanle L. A phase II trial of anastrazole in advanced, recurrent or persistent endometrial carcinoma: a Gynaecologic Oncology Group study. Gynecol Oncol 2000; 78 : 212-6. (Pubitemid 30650356)
11. Jeyarajah AR, Gallagher CJ, Blake PR. Long-term follow-up of gonadotropin-releasing hormone analog treatment for recurrent endometrial cancer. Gynecol Oncol 1996; 63 : 47-52. (Pubitemid 26337964)
12. L'Homme C, Vennin P, Callet N, et al. A multicenter phase II study with triptorelin (sustained release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French Anticancer Federation study. Gynecol Oncol 1999; 75 : 187-93. (Pubitemid 29523017)
13. Foster PA, Lawrence Woo LW, Barry VL, et al. The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer. Endocrinology 2008; 149 : 4035-42.
14. Fleming GF. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol 2007; 25 : 2983-90. (Pubitemid 47123163)
15. Thigpen JT, Blessing JA, DiSaia PJ, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1994; 12 : 1408-14. (Pubitemid 24206239)
16. Aapro MS, van Wijk FH, Bolis G, et al European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003; 14 : 441-8.
17. Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004; 22 : 3902-8. (Pubitemid 41079871)
18. Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 2004; 15 : 1173-8. (Pubitemid 39199303)
19. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2004; 22 : 2159-66. (Pubitemid 41095150)
20. du Bois A, Pfisterer J, Burchardi N, et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol Oncol 2007; 107 : 518-25. (Pubitemid 350160867)
21. Gebbia V, Testa A, Borsellino N, et al. Cisplatin and vinorelbine in advanced and/or metastatic adenocarcinoma of the endometrium: a new highly active chemotherapeutic regimen. Ann Oncol 2001; 12 : 767-72. (Pubitemid 32655084)
22. Sorbe B, Andersson H, Boman K, et al. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer 2008; 18 : 803-8. (Pubitemid 352020182)
23. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15 : 10-7. (Pubitemid 13194678)
24. McMeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol 2007; 106 : 16-22. (Pubitemid 46898605)
25. Aghajanian C, Sill MW, Darcy K, et al. A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer. A gynaecologic oncology group study. J Clin Oncol 2009; 27 : 5531.
26. Correa R, Mackay H, Hirte H, et al. A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: a trial of the PMH, U Chicago, and California Cancer Phase II Consortia. JCO 2010; 28 : 5038.
27. Fleming G, Sill M, Darcy K, et al. Phase II trial of Trastuzumab in women with advanced or recurrent, Her2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010; 116 : 15-20.
28. Oza AM, Elit L, Biagni J, et al. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer. J Clin Oncol 2006; 24 : 3003.
29. Oza AM, Elit L, Provencher D. A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. J Clin Oncol 2008; 26 : 5516.